View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Becton Dickinson & Co: 1 director

A director at Becton Dickinson & Co sold 2,838 shares at 223.330USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

Becton, Dickinson and Company: Update following closing of critical ca...

Our credit view of this issuer reflects its significant global scale and diversity, offset by its pricing pressure among lower tech products.

Moody’s ratings says Becton's hernia repair settlement is credit negat...

Moody's Ratings (Moody's) commented that Becton, Dickinson and Company's (Baa2 stable) announcement that it had reached an agreement to resolve the vast majority of its US product liability lawsuits involving hernia repair devices is credit negative. Per the settlement terms, Becton will make paymen...

Becton's hernia repair settlement is credit negative but reduces uncer...

Moody's Ratings (Moody's) commented that Becton, Dickinson and Company's (Baa2 stable) announcement that it had reached an agreement to resolve the vast majority of its US product liability lawsuits involving hernia repair devices is credit negative. Per the settlement terms, Becton will make paymen...

Becton, Dickinson and Company: Hernia repair settlement is credit nega...

Payouts will occur over a multiyear period, reducing the negative impact on key credit ratios.

Becton, Dickinson and Company: Combination of good organic growth supp...

Our credit view of this issuer reflects its significant global scale and diversity, offset by its pricing pressure among lower tech products.

Moody's Ratings; Becton's acquisition of Edwards' critical care will e...

Moody's Ratings commented that Becton, Dickinson and Company's (BD) announcement that it will acquire the critical care division of Edwards Lifesciences Corporation for a total enterprise value of $4.2 billion will bolster BD's presence in the critical care setting and is credit positive because of ...

Becton, Dickinson and Company: Acquisition of Edwards' critical care b...

The transaction modestly increases financial leverage but is credit positive on strategic fit and the positive impact on BD's growth and margins.

Moody's assigns Baa2 to Becton Dickinson's sr. notes; outlook stable

Moody's Investors Service ("Moody's") assigned Baa2 ratings to the new USD and EUR denominated senior unsecured notes offering of Becton, Dickinson and Company ("BD"). Net proceeds from the notes will be used to repay existing indebtedness and to cover associated fees and expenses. All other ratings...

Becton, Dickinson and Company: Update to credit analysis

Our credit view of this issuer reflects its excellent liquidity and its significant scale with high EBITDA margins.

Becton, Dickinson and Company: Update to credit analysis following upg...

Our credit view of this issuer reflects its excellent liquidity and its significant scale with high EBITDA margins, offset by its history of significant debt financed acquisitions.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch